BCR-ABL activity measured by 50% inhibitory concentration for
imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of
patients with chronic myeloid leukemia does not predict
treatment response.

J 2012

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ et. al.

Základní údaje

Originální název

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

Autoři

ŠIMARA, Pavel (203 Česká republika, domácí), Martina PETERKOVÁ (203 Česká republika, domácí), Stanislav STEJSKAL (203 Česká republika, domácí), Michaela POTĚŠILOVÁ (203 Česká republika, domácí), Irena KRONTORÁD KOUTNÁ (203 Česká republika, garant, domácí), Zdeněk RÁČIL (203 Česká republika, domácí), Filip RÁZGA (703 Slovensko, domácí), Tomáš JURČEK (203 Česká republika, domácí), Dana DVOŘÁKOVÁ (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Leukemia & lymphoma, England, Informa Healthcare, 2012, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.301

Kód RIV

RIV/00216224:14330/12:00059688

Organizační jednotka

Fakulta informatiky

DOI

http://dx.doi.org/10.3109/10428194.2012.656104

UT WoS

000306566000035

Klíčová slova anglicky

p-CrkL; chronic myeloid leukemia; imatinib

Štítky

cbia-web

Změněno: 2. 3. 2018 10:12, Mgr. Pavel Šimara, Ph.D.

Anotace

V originále

In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.

Návaznosti

GBP302/12/G157, projekt VaV

Název: Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii

Investor: Grantová agentura ČR, Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii

MSM0021622430, záměr

Název: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Citovat

ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ a Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leukemia & lymphoma. England: Informa Healthcare, 2012, roč. 53, č. 8, s. 1627-1629. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.656104.

@article{979222,
   author = {Šimara, Pavel and Peterková, Martina and Stejskal, Stanislav and Potěšilová, Michaela and Krontorád Koutná, Irena and Ráčil, Zdeněk and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Mayer, Jiří},
   article_location = {England},
   article_number = {8},
   doi = {http://dx.doi.org/10.3109/10428194.2012.656104},
   keywords = {p-CrkL; chronic myeloid leukemia; imatinib},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & lymphoma},
   title = {BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.},
   url = {http://www.ncbi.nlm.nih.gov/pubmed/22233112},
   volume = {53},
   year = {2012}
}

TY  - JOUR
ID  - 979222
AU  - Šimara, Pavel - Peterková, Martina - Stejskal, Stanislav - Potěšilová, Michaela - Krontorád Koutná, Irena - Ráčil, Zdeněk - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Mayer, Jiří
PY  - 2012
TI  - BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
JF  - Leukemia & lymphoma
VL  - 53
IS  - 8
SP  - 1627-1629
EP  - 1627-1629
PB  - Informa Healthcare
SN  - 10428194
KW  - p-CrkL
KW  - chronic myeloid leukemia
KW  - imatinib
UR  - http://www.ncbi.nlm.nih.gov/pubmed/22233112
L2  - http://www.ncbi.nlm.nih.gov/pubmed/22233112
N2  - In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.
ER  -

ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ a Jiří MAYER. BCR-ABL activity measured by 50\%{} inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. \textit{Leukemia \&{} lymphoma}. England: Informa Healthcare, 2012, roč.~53, č.~8, s.~1627-1629. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.656104.

Podrobný výpis o publikaci